Carmenta Bioscience is a privately held, medical technology company focused on advancing maternal and fetal health by applying a systems biology approach to the diagnosis and prediction of preeclampsia. Carmenta™s products in development combine proprietary computational algorithms with novel serum protein measurements to classify pregnant mothers at risk for preeclampsia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/07/13 | $2,000,000 | Seed |
Life Science Angels | undisclosed |
